Real-world Data From the Swiss Lenalidomide in MDS Del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS Del(5q)
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Abdallah M, Reichard K, Gangat N, Tefferi A Blood Cancer J. 2024; 14(1):49.
PMID: 38499527 PMC: 10948768. DOI: 10.1038/s41408-024-01027-5.
References
1.
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M
. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011; 118(14):3765-76.
DOI: 10.1182/blood-2011-01-330126.
View
2.
Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, cermak J, Del Canizo C
. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17):2943-64.
PMC: 3811170.
DOI: 10.1182/blood-2013-03-492884.
View
3.
Cazzola M
. Myelodysplastic Syndromes. N Engl J Med. 2020; 383(14):1358-1374.
DOI: 10.1056/NEJMra1904794.
View
4.
Fenaux P, Haase D, Santini V, Sanz G, Platzbecker U, Mey U
. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 32(2):142-156.
DOI: 10.1016/j.annonc.2020.11.002.
View
5.
Giagounidis A, Kulasekararaj A, Germing U, Radkowski R, Haase S, Petersen P
. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide. Leukemia. 2011; 26(4):855-8.
DOI: 10.1038/leu.2011.268.
View